A long-listed, low-debt medicine maker that grows sales steadily and pays a dependable, rising cash dividend — but the profit it keeps from each taka of sales has been getting thinner.

The IBN SINA Pharmaceutical Industry PLC makes and sells medicines and pharmaceutical products in Bangladesh. It is one of the country's long-standing drug makers, and it has been listed on the Dhaka Stock Exchange since 1989 — more than 35 years — so it has lived through many ups and downs in the economy and the market.

It sits in the pharmaceuticals and chemicals group, one of the larger and more closely watched parts of the market, alongside big names such as Square Pharmaceuticals and multinationals like Marico and Reckitt Benckiser. By sales it has grown into a sizeable domestic manufacturer, with yearly revenue of about 1,188 crore taka in its most recent financial year (which ends on 30 June).

In share-count terms the company is not large — it has about 3.12 crore shares and a paid-up capital of about 31.2 crore taka — but over the years it has built up sizeable reserves of about 360.8 crore taka from retained profits, many times its paid-up capital. That points to a business that has quietly kept money inside the company over a long period.

IBN SINA's money comes from making pharmaceutical products and selling them — to pharmacies, hospitals, doctors and, ultimately, the patients who need medicines. Like most drug makers, its sales tend to be fairly steady, because people need medicines in good times and bad.

Sales have been rising well: revenue went from about 848 crore taka (financial year 2022) to about 912.5 crore, then about 1,137 crore, and about 1,188 crore in the latest year. That is healthy, consistent growth in the top line.

But selling more has not turned into much more operating profit — the profit from its core business was about 86.1 crore taka in 2022 and about 94.6 crore in 2025, roughly flat even as sales grew strongly. In plain terms, it is selling more but keeping a thinner slice of each sales taka as profit — most likely because the cost of making and selling medicines has risen. This is the single most important thing to understand about how the business is doing.

Yes, clearly. IBN SINA has been profitable every single year. Net profit was about 48.9 crore taka in 2021, then about 60.6, 60.5, 67.1, and about 63.3 crore in the latest year (2025). Over the full 2021–2025 stretch, profit is up about 29%.

Earnings per share — the yearly profit shared out over all the shares — followed the same path: about 15.66 taka in 2021, rising to about 21.46 taka in 2024, then easing to about 20.27 taka in 2025. That is a small dip of a few percent in the latest year, mostly because costs rose faster than sales.

More recent quarterly updates the company has filed suggest the pause may be temporary: earnings in the first nine months of its 2026 financial year came to about 19.94 taka per share, well ahead of about 15.02 taka in the same stretch a year earlier. Still, the medium-term picture is of a company that makes steady money but does not grow its profit in a straight line.

On safety, IBN SINA looks solid. It carries little debt. For every 100 taka of its own money (shareholders' equity), it owed only about 24 taka of borrowings in the latest year — up from around 11 to 15 taka in earlier years, but still low. Its own money in the business has grown steadily, from about 262.5 crore taka (2022) to about 399.8 crore (2025), and it holds large accumulated reserves of about 360.8 crore taka. A well-known outside rating agency recently gave the company an 'AA+' grade — a high mark — with a stable outlook.

The asset value backing each share — what the company owns minus what it owes, per share — has risen every year: about 68.69 taka (2021), then 83.36, 96.68, 111.94, and about 125.69 taka in 2025. A steadily rising asset value per share like this is a healthy sign.

The one thing to keep an eye on is cash and spending. The company has been investing heavily to expand — its yearly capital spending climbed from about 36.5 crore taka (2022) to about 97.6 crore (2025). In some years that spending was more than the cash its operations generated (operating cash flow bounced around: about 41.9, 87.7, 39.0 and 72.4 crore taka), which is why its borrowing has crept up. That is normal for a company building for the future, but it is worth watching that the new investment eventually pays off in higher profit.

IBN SINA is a reliable dividend payer, and always in cash — it has not been handing out bonus shares. For the latest year it declared a 64% cash dividend, which is 6.4 taka per share on the 10-taka face value of each share.

The dividend has climbed steadily: 47% (2021), then 60%, 60%, 63% and 64% — a slow, dependable rise year after year, backed by a long history of paying.

Importantly, the payout looks safe. Out of about 20.27 taka of profit earned per share last year, it paid out about 6.4 taka — only around a third — keeping the rest inside the company to fund its growth. A dividend that uses well under half of profit has plenty of room to continue, which is reassuring for income-focused holders. (How much that dividend is worth against today's price — the yield — moves with the price and is shown live beside this report.)

IBN SINA's real edge is trust and staying power. It is a long-established, recognised Bangladeshi medicine brand, listed since 1989 and profitable throughout — and in a business where doctors and patients stick with names they trust, that reputation is worth a lot. Its low debt and large reserves also let it keep investing through good years and bad.

On raw profitability, though, it is middle-of-the-pack rather than a standout. It earns roughly 16 taka of profit a year for every 100 taka of shareholders' money in the business — broadly similar to Square Pharmaceuticals (around 15 taka), but far below the asset-light multinationals in the same sector such as Marico (around 78 taka) and Reckitt Benckiser (around 45 taka), and below Kohinoor Chemical (around 26 taka). Those rivals squeeze much more profit from each taka of their own money.

Its earnings also dipped slightly in the latest year while several of those peers grew theirs, and — as noted — the profit it keeps from each taka of sales has been shrinking. So the honest picture is a dependable, well-run domestic manufacturer with a strong balance sheet and a trusted name, but without the premium pricing power or high efficiency of the sector's very best.

• Long, unbroken track record. Listed since 1989 and profitable every year in the record — a proven, established medicine maker, not an untested newcomer.
• Sales growing steadily. Revenue rose from about 848 crore taka (2022) to about 1,188 crore (2025), and the rising asset value per share (about 68.69 up to 125.69 taka) shows real value building up inside the company.
• Very strong, low-debt balance sheet. It owes only about 24 taka for every 100 taka of its own money, holds about 360.8 crore taka of reserves, and carries a high 'AA+' outside credit rating — it could comfortably ride out a bad year.
• Dependable, rising cash dividend. A steadily growing cash payout (47% up to 64% of face value over five years) that uses only about a third of profit, so it has room to keep going.
• Confident owners. Sponsors hold a large 44.68% stake, and institutions have been raising theirs (from about 21.81% to 25.19%) — a sign that informed investors are backing it.

• Thinning margins. Sales grew strongly from 2022 to 2025 (about 848 to 1,188 crore taka), but core operating profit barely moved (about 86.1 to 94.6 crore taka) — each taka of sales is bringing home less profit than before.
• Profit has stopped climbing. Net profit slipped from about 67.1 crore taka (2024) to about 63.3 crore (2025), and per-share earnings eased from about 21.46 to 20.27 taka — a small step back after years of growth.
• Heavy spending funded by more debt. Yearly investment jumped from about 36.5 to 97.6 crore taka, at times outrunning the cash the business generated, and borrowings rose from about 36.8 to 97.5 crore taka. If the expansion does not lift profit, that spending will weigh on returns.
• Bumpy cash generation. Operating cash flow has swung around (about 41.9, 87.7, 39.0 and 72.4 crore taka), so the cash coming in is not always steady.
• Middling efficiency and a modest free float. Its profit on shareholders' money trails the sector's premium multinationals, and with sponsors and institutions holding most of the shares, relatively few trade freely in the market.

The IBN SINA Pharmaceutical Industry is the kind of share that suits a patient, cautious investor — someone who wants a steady, established business with a safe balance sheet and a dependable, slowly rising cash dividend, rather than fast excitement. Its long history, low debt and reliable payout are its strongest points.

It is less suited to someone chasing rapid growth or a quick gain. Profit flattened in the latest year, margins are thinning, and the company is spending heavily to expand — a plan that needs time to prove itself. A risk-taker looking for a fast mover will probably find it too slow.

The single most important thing to watch is whether that heavy investment starts lifting profit again and halts the slide in margins. Whether the current price is reasonable is a separate question, answered by the live value estimate beside this report — this write-up is about the durable quality of the business, not the price on any given day.